Understanding and Addressing Multiple Myeloma Disparities

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and evaluate protocols for conducting research focused on ethnic and racial minorities affected by Multiple Myeloma (MM) using cancer registry data. The investigators will identify, recruit, and survey patients from diverse backgrounds, including African Americans, Latinos, Asian Americans, Native Hawaiians, Pacific Islanders, and non-Hispanic Whites, to gather information on factors related to MM etiology and survival. Initially, a pilot phase will contact 400 eligible patients to assess the feasibility of the recruitment and survey process, with plans to expand to a larger cohort of 1,000 patients per ethnic group across California. The ultimate goal is to inform best practices for recruiting minority populations and to lay the groundwork for larger studies on MM.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with a first primary pathologically confirmed case of Multiple Myeloma within the previous 5 years
* At least 21 years of age at the time of diagnosis
* Must have been diagnosed in one of the 48 counties in California
* Participant must be alive
* Identify as one of the following: African American, Latino, Asian American/Native Hawaiian/Pacific Islander, Non-Hispanic White

Exclusion Criteria:

* People who have not been diagnosed with Multiple Myeloma
* Under the age of 21
* Pregnant
* Prisoner

Where it's running

• University of California Davis Comprehensive Cancer Center
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Luis Carvajal-Carmona, PhD — University of California, Davis
• Study coordinator: Luis Carvajal-Carmona, PhD
• Email: lgcarvajal@ucdavis.edu
• Phone: 5307529654

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.